Literature DB >> 7061920

Triamterene urolithiasis: solubility, pk, effect on crystal formation, and matrix binding of triamterene and its metabolites.

P G Werness, J H Bergert, L H Smith.   

Abstract

The commonly used diuretic Tri and its metabolites have been identified recently as major components of some kidney stones. We have carried out basic physical chemical studies to determine the mechanism of Tri incorporation into kidney stones. The solubility and pK of Tri and its major metabolites, Tri-OH and the Tri-So4, have been determined at 37 C in 0.15 M NaCl. The effect of Tri and its metabolites on crystal formation has been measured in the calcium oxalate monohydrate, hydroxyapatite, and uric acid crystal systems. Tri and its metabolites do not promote crystal nucleation, growth, or aggregation in any of these crystal systems and are not incorporated as these crystals form. We can demonstrate binding of Tri and its metabolites to the protein matrix isolated from kidney stones. These data suggest that Tri and its metabolites to the protein matrix isolated from kidney stones. These data suggest that Tri and its metabolites do not promote the formation of kidney stones but rather become incorporated into existing stones or stone nidi by binding to the protein matrix found in all kidney stones.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061920

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Does triamterene cause renal calculi?

Authors:  R G Woolfson; M A Mansell
Journal:  BMJ       Date:  1991-11-16

Review 2.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

3.  Triamterene and renal stone formation: the influence of triamterene and triamterene stones on calcium oxalate crystallization.

Authors:  D J White; G H Nancollas
Journal:  Calcif Tissue Int       Date:  1987-02       Impact factor: 4.333

4.  Sulphate conjugation of p-hydroxytriamterene by platelet phenol sulphotransferase: assay conditions and correlation with metabolism in man.

Authors:  C Reiter; P G Werness; J Van Loon; L H Smith; R M Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

Review 5.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Pharmacodynamics of basic triamterene derivatives.

Authors:  H Priewer; H Spahn; E Mutschler
Journal:  Pharm Res       Date:  1986-04       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.